Kimberly-Clark Seeks EU Antitrust Approval for $40 Billion Kenvue Acquisition

Kimberly-Clark has officially filed for European Union antitrust approval for its proposed $40 billion acquisition of Kenvue, the consumer health company behind brands like Tylenol and Listerine. The request, which appeared on the European Commission's website, marks a significant step in the regulatory process for the massive transaction.

Deal Nears Key Regulatory Hurdle

The formal submission to the EU's competition authority initiates a review to assess the deal's impact on the consumer products market. This is a crucial step for the merger, which was first announced in November of last year. Both companies have previously stated they expect the transaction to close in the second half of 2026, contingent on regulatory clearances.

Strategic Rationale and Financials

The acquisition is a transformative move for Kimberly-Clark, set to significantly expand its portfolio with a host of major consumer brands. Key details of the proposed deal include:

Ad

• Acquired Brands: Kenvue's portfolio includes Listerine mouthwash, Tylenol pain reliever, and skincare lines Neutrogena and Aveeno.
• Projected Synergies: Kimberly-Clark has forecast $2.1 billion in annual cost savings resulting from the integration.
• Combined Revenue: The merged entity is expected to generate annual revenues of approximately $32 billion.

Market Implications

Investors will be closely watching the European Commission's decision, as it represents one of the final major hurdles for the deal. A smooth approval process would keep the acquisition on track for its targeted closing date, while any potential demands for concessions or an in-depth probe could introduce delays and uncertainty.